Is Iteos Therapeutics Stock a Good Investment?
Iteos Therapeutics Investment Advice | ITOS |
- Examine Iteos Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Iteos Therapeutics' leadership team and their track record. Good management can help Iteos Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Iteos Therapeutics' business and its evolving consumer preferences.
- Compare Iteos Therapeutics' performance and market position to its competitors. Analyze how Iteos Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Iteos Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Iteos Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Iteos Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Iteos Therapeutics is a good investment.
Sell | Buy |
Buy
Market Performance | Solid | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Iteos Therapeutics Stock
Researching Iteos Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.79. Some equities with similar Price to Book (P/B) outperform the market in the long run. Iteos Therapeutics recorded a loss per share of 3.05. The entity had not issued any dividends in recent years.
To determine if Iteos Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Iteos Therapeutics' research are outlined below:
| Iteos Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 35 M. Net Loss for the year was (134.41 M) with profit before overhead, payroll, taxes, and interest of 35 M. | |
| Iteos Therapeutics currently holds about 791.86 M in cash with (98.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 22.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Iteos Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: SHAREHOLDER ALERT Morris Kandinov Investigating AVDX, IRTC, HAYW, and ITOS Shareholders are ... |
Iteos Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Iteos Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Iteos Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Iteos Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Iteos Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-10 | 2022-09-30 | 0.1 | 0.03 | -0.07 | 70 | ||
2021-05-13 | 2021-03-31 | -0.48 | -0.39 | 0.09 | 18 | ||
2025-05-08 | 2025-03-31 | -0.9035 | -0.8 | 0.1035 | 11 | ||
2020-11-12 | 2020-09-30 | -0.36 | -0.48 | -0.12 | 33 | ||
2024-11-05 | 2024-09-30 | -0.89 | -1.0515 | -0.1615 | 18 | ||
2024-03-06 | 2023-12-31 | -1.03 | -0.85 | 0.18 | 17 | ||
2024-05-10 | 2024-03-31 | -1.26 | -1.07 | 0.19 | 15 | ||
2023-03-15 | 2022-12-31 | 0.33 | 0.56 | 0.23 | 69 |
Iteos Therapeutics Target Price Consensus
Iteos target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Iteos Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Strong Buy |
Most Iteos analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Iteos stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Iteos Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationIteos Therapeutics Target Price Projection
Iteos Therapeutics' current and average target prices are 10.09 and 23.50, respectively. The current price of Iteos Therapeutics is the price at which Iteos Therapeutics is currently trading. On the other hand, Iteos Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Iteos Therapeutics Market Quote on 4th of August 2025
Target Price
Analyst Consensus On Iteos Therapeutics Target Price
Iteos Therapeutics Analyst Ratings
Iteos Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Iteos Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Iteos Therapeutics' financials, market performance, and future outlook by experienced professionals. Iteos Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Iteos Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Iteos Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Iteos Therapeutics backward and forwards among themselves. Iteos Therapeutics' institutional investor refers to the entity that pools money to purchase Iteos Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Vestal Point Capital Lp | 2025-03-31 | 900 K | Geode Capital Management, Llc | 2025-03-31 | 650.1 K | Renaissance Technologies Corp | 2025-03-31 | 645.6 K | Goldman Sachs Group Inc | 2025-03-31 | 587.4 K | State Street Corp | 2025-03-31 | 582 K | Jacobs Levy Equity Management, Inc. | 2025-03-31 | 557.9 K | Acadian Asset Management Llc | 2025-03-31 | 536.8 K | Millennium Management Llc | 2025-03-31 | 348.4 K | Nuveen, Llc | 2025-03-31 | 303.6 K | Blackrock Inc | 2025-03-31 | 4.5 M | Ra Capital Management, Llc | 2025-03-31 | 3.6 M |
Iteos Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 445.69 M.Market Cap |
|
Iteos Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.25) | (0.26) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.23) | (0.24) |
Determining Iteos Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Iteos Therapeutics is a good buy. For example, gross profit margin measures Iteos Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Iteos Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Iteos Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Iteos Therapeutics. Check Iteos Therapeutics' Beneish M Score to see the likelihood of Iteos Therapeutics' management manipulating its earnings.
Evaluate Iteos Therapeutics' management efficiency
Iteos Therapeutics has return on total asset (ROA) of (0.1454) % which means that it has lost $0.1454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2368) %, meaning that it created substantial loss on money invested by shareholders. Iteos Therapeutics' management efficiency ratios could be used to measure how well Iteos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.21 in 2025. Return On Capital Employed is likely to drop to -0.26 in 2025. At this time, Iteos Therapeutics' Net Tangible Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 186.3 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 4.1 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 14.58 | 8.77 | |
| Tangible Book Value Per Share | 14.58 | 8.77 | |
| Enterprise Value Over EBITDA | (1.09) | (1.14) | |
| Price Book Value Ratio | 0.53 | 0.50 | |
| Enterprise Value Multiple | (1.09) | (1.14) | |
| Price Fair Value | 0.53 | 0.50 | |
| Enterprise Value | 199.9 M | 189.9 M |
The management team at Iteos Therapeutics has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Beta 1.494 |
Basic technical analysis of Iteos Stock
As of the 4th of August, Iteos Therapeutics retains the Risk Adjusted Performance of 0.1496, market risk adjusted performance of 2.2, and Downside Deviation of 2.09. Iteos Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Iteos Therapeutics mean deviation, information ratio, as well as the relationship between the Information Ratio and downside variance to decide if Iteos Therapeutics is priced fairly, providing market reflects its last-minute price of 10.09 per share. Given that Iteos Therapeutics has jensen alpha of 0.609, we strongly advise you to confirm Iteos Therapeutics's regular market performance to make sure the company can sustain itself at a future point.Iteos Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Iteos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Iteos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Iteos Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Iteos Therapeutics' Outstanding Corporate Bonds
Iteos Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Iteos Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Iteos bonds can be classified according to their maturity, which is the date when Iteos Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ITC HLDGS P Corp BondUS465685AH81 | View | |
| ITC HLDGS P Corp BondUS465685AK11 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| US465685AQ80 Corp BondUS465685AQ80 | View | |
| ITC HLDGS P Corp BondUS465685AP08 | View | |
| ITC 495 22 SEP 27 Corp BondUS465685AR63 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand Iteos Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Iteos Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1496 | |||
| Market Risk Adjusted Performance | 2.2 | |||
| Mean Deviation | 2.06 | |||
| Semi Deviation | 1.6 | |||
| Downside Deviation | 2.09 | |||
| Coefficient Of Variation | 555.51 | |||
| Standard Deviation | 3.61 | |||
| Variance | 13.01 | |||
| Information Ratio | 0.1486 | |||
| Jensen Alpha | 0.609 | |||
| Total Risk Alpha | 0.1655 | |||
| Sortino Ratio | 0.256 | |||
| Treynor Ratio | 2.19 | |||
| Maximum Drawdown | 19.21 | |||
| Value At Risk | (2.72) | |||
| Potential Upside | 5.84 | |||
| Downside Variance | 4.38 | |||
| Semi Variance | 2.55 | |||
| Expected Short fall | (3.02) | |||
| Skewness | 2.27 | |||
| Kurtosis | 9.9 |
| Risk Adjusted Performance | 0.1496 | |||
| Market Risk Adjusted Performance | 2.2 | |||
| Mean Deviation | 2.06 | |||
| Semi Deviation | 1.6 | |||
| Downside Deviation | 2.09 | |||
| Coefficient Of Variation | 555.51 | |||
| Standard Deviation | 3.61 | |||
| Variance | 13.01 | |||
| Information Ratio | 0.1486 | |||
| Jensen Alpha | 0.609 | |||
| Total Risk Alpha | 0.1655 | |||
| Sortino Ratio | 0.256 | |||
| Treynor Ratio | 2.19 | |||
| Maximum Drawdown | 19.21 | |||
| Value At Risk | (2.72) | |||
| Potential Upside | 5.84 | |||
| Downside Variance | 4.38 | |||
| Semi Variance | 2.55 | |||
| Expected Short fall | (3.02) | |||
| Skewness | 2.27 | |||
| Kurtosis | 9.9 |
Consider Iteos Therapeutics' intraday indicators
Iteos Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Iteos Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Iteos Therapeutics Corporate Filings
| 1st of August 2025 Other Reports | ViewVerify | |
| 25th of July 2025 Other Reports | ViewVerify | |
| 22nd of July 2025 Other Reports | ViewVerify | |
8K | 21st of July 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Iteos Stock media impact
There is far too much social signal, news, headlines, and media speculation about Iteos Therapeutics that are available to investors today. This information is accessible both publicly - through Iteos Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Iteos-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Iteos Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Iteos Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Iteos Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Iteos Therapeutics alpha.
Iteos Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Iteos Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Iteos Therapeutics Historical Investor Sentiment
Investor biases related to Iteos Therapeutics' public news can be used to forecast risks associated with an investment in Iteos. The trend in average sentiment can be used to explain how an investor holding Iteos can time the market purely based on public headlines and social activities around Iteos Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Iteos Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Iteos Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Iteos Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Iteos Therapeutics.
Iteos Therapeutics Corporate Management
| Matthew Gall | Chief Officer | Profile | |
| Matthew MBA | Chief Officer | Profile | |
| Ryan Baker | Head Relations | Profile | |
| Joanne MD | Chief Officer | Profile | |
| Adi Osovsky | Executive Legal | Profile |
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.